Description

The High-Concentration Formulation (HCF) of Hyrimoz (adalimumab-adaz) is a citrate-free version with a concentration of 100 mg/mL. This formulation is designed to provide a 50% reduction in injection volume compared to the standard version, which can help improve the administration experience and potentially reduce injection-site pain for patients with conditions like hidradenitis suppurativa and Crohn's disease.

Best for

Reduced injection volume preference, Citrate-free medication needs, Enhanced injection comfort and High-dose biologic requirements

Description

Hyrimoz (adalimumab-adaz) is a prescription biologic medication and an FDA-approved biosimilar to Humira. As a Tumor Necrosis Factor (TNF) blocker, it is used to treat chronic inflammatory diseases including rheumatoid arthritis (RA), juvenile idiopathic arthritis (JIA), psoriatic arthritis (PsA), ankylosing spondylitis (AS), Crohn’s disease (CD), ulcerative colitis (UC), and plaque psoriasis. It is available as a subcutaneous injection via the Sensoready Pen autoinjector or a prefilled syringe.

Best for

Rheumatoid arthritis patients, Crohn's disease management, Plaque psoriasis treatment and Biosimilar therapy seekers

Description

Hyrimoz is an FDA-approved adalimumab biosimilar and TNF blocker used as a subcutaneous injection to treat inflammatory diseases. It is commonly prescribed for patients with rheumatoid arthritis, plaque psoriasis, Crohn's disease, ulcerative colitis, and ankylosing spondylitis. As a biologic therapy, it helps reduce inflammation and manage symptoms by targeting tumor necrosis factor (TNF) proteins in the body.

Best for

rheumatoid arthritis patients, Crohn's disease therapy, plaque psoriasis treatment, chronic inflammation management and biologic therapy users